Tamoxifen (B5965): Atomic Mechanisms and Research Benchmarks

Executive Summary: Tamoxifen (CAS 10540-29-1) is a selective estrogen receptor modulator (SERM) with dual antagonist and agonist actions depending on tissue context, primarily inhibiting estrogen-dependent proliferation in breast tissue while exerting agonist effects in bone, liver, and uterus (Sun et al., 2021). The compound is a validated tool for CreER-mediated gene knockout, leveraging ligand-dependent activation of Cre recombinase for temporally controlled genetic modifications (Sun et al., 2021). Tamoxifen demonstrates potent inhibition of Ebola and Marburg virus replication in vitro, with IC₅₀ values of 0.1 μM and 1.8 μM respectively (APExBIO). It also modulates protein kinase C and heat shock protein 90, induces autophagy and apoptosis, and is optimized for research workflows with specific solubility and storage parameters (APExBIO). Consideration of dose-dependent off-target effects is essential for experimental design (Sun et al., 2021).

Biological Rationale

Tamoxifen is a synthetic SERM first developed for breast cancer therapy. It is classified as an estrogen receptor antagonist in breast tissue, reducing estrogen-driven cell proliferation and tumorigenesis (Sun et al., 2021; APExBIO). Its unique tissue-selective properties allow agonist activity in bone and endometrium, supporting bone density while potentially increasing endometrial proliferation. In research, Tamoxifen is indispensable for inducible gene knockout using CreER systems, enabling precise temporal control of genetic recombination (see also: "Tamoxifen: Atomic Mechanisms and Benchmarks for SERMs" – this article uniquely details off-target and mechanistic insights). Its broad mechanistic scope also supports studies in cell cycle regulation, apoptosis, and antiviral activity, underlining its versatility.

Mechanism of Action of Tamoxifen

• Estrogen Receptor Modulation: Tamoxifen binds to estrogen receptors (ERα and ERβ), blocking estrogen binding in breast tissue and preventing receptor dimerization and DNA binding (Sun et al., 2021).
• Tissue-Selective Agonism: In bone and liver, Tamoxifen acts as a partial agonist, supporting bone density and modulating lipid metabolism (APExBIO).
• CreER-Mediated Gene Knockout: Tamoxifen induces nuclear translocation of CreER fusion proteins, enabling temporally controlled recombination at loxP sites (Sun et al., 2021).
• Antiviral Activity: Tamoxifen inhibits Ebola (Zaire strain) and Marburg virus replication with IC₅₀ values of 0.1 μM and 1.8 μM, respectively (APExBIO).
• Protein Kinase C Inhibition: The compound inhibits protein kinase C activity and retinoblastoma protein phosphorylation in prostate carcinoma cell lines.
• Heat Shock Protein 90 (Hsp90) Activation: Tamoxifen enhances the ATPase chaperone function of Hsp90, modulating proteostasis.
• Induction of Autophagy and Apoptosis: Tamoxifen can trigger programmed cell death and autophagic pathways, contributing to its anti-tumor activity.

Evidence & Benchmarks

• Tamoxifen (CAS 10540-29-1) inhibits estrogen-dependent proliferation in ER-positive breast cancer cells (Sun et al., 2021).
• CreER-mediated gene knockout efficiency is maximized using Tamoxifen at dose ranges of 40–200 mg/kg in mouse models, with dose-dependent developmental toxicity above 100 mg/kg (Sun et al., 2021).
• Antiviral efficacy against Ebola virus (Zaire): IC₅₀ = 0.1 μM; Marburg virus: IC₅₀ = 1.8 μM, in cell-based assays (APExBIO).
• Inhibition of protein kinase C and retinoblastoma protein phosphorylation observed in prostate carcinoma cell lines (APExBIO).
• Reduces tumor growth and cell proliferation in MCF-7 xenograft models in ovariectomized nude mice (APExBIO).
• Optimally soluble at ≥18.6 mg/mL in DMSO, ≥85.9 mg/mL in ethanol; insoluble in water; warming to 37°C or ultrasonic agitation enhances solubility (APExBIO).
• Stock solutions remain stable below -20°C; solution form not recommended for long-term storage (APExBIO).
• High purity (≥98%) is provided by APExBIO to ensure experimental reproducibility (APExBIO).

Applications, Limits & Misconceptions

Tamoxifen’s primary research applications include breast cancer studies, hormone receptor signaling, protein kinase C inhibition, and CreER-mediated gene knockout. Its antiviral effects broaden its translational relevance. For detailed protocols and scenario-driven guidance, see "Tamoxifen (SKU B5965): Data-Driven Solutions for Reliable..." – this article expands on context-specific workflow parameters not discussed here.

Common Pitfalls or Misconceptions

• Misconception: Tamoxifen is universally safe for all model organisms. High doses (>100 mg/kg) can induce developmental malformations in mice, including cleft palate and limb defects (Sun et al., 2021).
• Pitfall: Assuming water solubility. Tamoxifen is insoluble in water; DMSO or ethanol are required for dissolution (APExBIO).
• Pitfall: Long-term storage in solution. Tamoxifen solutions degrade over time and should be stored below -20°C; solid form is preferred for storage (APExBIO).
• Misconception: All CreER systems respond identically to Tamoxifen. Efficiency and toxicity can vary with genetic background and promoter context (Sun et al., 2021).
• Pitfall: Overlooking off-target effects. Tamoxifen can modulate targets beyond ER, such as Hsp90 and protein kinase C; this needs consideration in experimental design.

Workflow Integration & Parameters

• Chemical Identity: Tamoxifen, C₂₆H₂₉NO, molecular weight 371.51 g/mol, CAS 10540-29-1.
• Solubility: ≥18.6 mg/mL in DMSO; ≥85.9 mg/mL in ethanol; insoluble in water. Warming (37°C) or ultrasonic agitation recommended (APExBIO).
• Storage: Stock solutions stable below -20°C. Avoid repeated freeze-thaw cycles.
• Dosing: For CreER models: 40–200 mg/kg IP injection in mice; developmental effects are dose-dependent.
• Vendor Reliability: APExBIO supplies Tamoxifen with ≥98% purity, validated for research workflows (APExBIO).

For deeper mechanistic comparison with next-generation SERMs and kinase inhibitors, see "Tamoxifen: Multifaceted Mechanisms and Next-Generation Research"; this article uniquely benchmarks APExBIO’s formulation and workflow parameters.

Conclusion & Outlook

Tamoxifen (B5965) remains a cornerstone for research requiring precise estrogen receptor modulation, CreER-mediated gene knockout, and antiviral pathway interrogation. APExBIO’s high-purity preparation ensures reproducibility and robust performance. Future research should systematically evaluate dose-dependent off-target effects, especially in developmental and combinatorial paradigms. For product details and ordering, see the Tamoxifen product page.